The GORUN Study: Gradual Onset of RUNning and Knee Joint Health in Novice Runners

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age35+
SponsorUniversity of British Columbia

About this trial

Knee osteoarthritis (OA) is a debilitating disease affecting millions worldwide. Exercise is a core treatment for knee OA, and is advocated by all clinical guidelines. Running is a common exercise that is accessible and evokes a number of positive physical and psychological benefits. However, the appropriateness of recreational running in the presence of knee OA is unclear.

A growing literature base appears to suggest that running may not be deleterious to the health - especially at the knee joint - of people with knee OA. Our recent research has focused on examining a number of health outcomes relevant to knee OA in older individuals with knee OA, but has been limited to experienced runners. This study will address that limitation by focusing on how novice (new) runners respond to a new running program.

Eligibility criteria

Qualifiers

have been running consistently for no more than six months at time of enrolment, with a cumulative weekly volume of less than 5 kilometres OR have yet to take up recreational running consistently

are comfortable running and walking on a treadmill for at least 30 minutes

have definitive knee OA as diagnosed using x-rays

report having experienced frequent knee pain over the past 3 months

Disqualifiers

have an inflammatory arthritic condition (e.g. gout or rheumatoid arthritis)

have a presence of any health condition (other than OA in the knee OA group) affecting normal movement or that precludes engaging in moderate to high impact activities such as running

cannot safely fit into the MRI scanner

presence of metallic implants (including pace makers, brain aneurysm clips, stents, cochlear implants, artificial heart valves, and prostheses)

Trial design

Treatments tested in this trial

  • Running volume increase

Treatment groups

80 Participants
are divided into 2 treatment groups

Sponsors and collaborators